부산대학교 도서관

This article discusses the successful treatment of four patients with refractory systemic lupus erythematosus (SLE) and neuropsychiatric manifestations using anifrolumab, a monoclonal antibody. The patients had various clinical characteristics, including acute confusional state, anxiety disorder, mood disorder, cerebrovascular disease, myelopathy, panniculitis, nephritis, pericarditis, leucopenia, haemolytic anaemia, thrombocytopenia, and aseptic meningitis. Anifrolumab treatment resulted in improvements in symptoms and serological abnormalities, allowing for the tapering of prednisolone without relapse of neuropsychiatric symptoms. The study suggests that anifrolumab may be an effective treatment option for refractory SLE with neuropsychiatric manifestations, although further research is needed. [Extracted from the article]